Contraindications
- Beta-lactam (penicillin, cephalosporin) hypersensitivity
- Previous flucloxacillin-associated jaundice or hepatic dysfunction
Dosing: Adult
- Staphylococcal infections (oral, adults and children over 10): 250 to 500 mg three times daily, 1 hour before or 2 hours after food
- Osteomyelitis, endocarditis: Up to 8 g/day in divided doses every 6 to 8 hours
- Surgical prophylaxis: 1 to 2 g intravenously at induction, then 500 mg every 6 hours for up to 72 hours
Dosing: Altered kidney function
Flucloxacillin is partly excreted in urine (20% to 50% of an oral dose) and is not removed by hemodialysis. The Irish label usually needs no dose reduction in kidney impairment; below creatinine clearance (CrCl) 10 mL/min it advises a lower dose or longer interval, with high-dose regimens capped at 1 g every 8 to 12 hours. It has no US FDA label.
Kidney function measure: Irish summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min); single threshold at 10 mL/min.
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 250 to 500 mg orally three times daily; up to 8 g/day in divided doses every 6 to 8 hours for osteomyelitis or endocarditis (SmPC).
- CrCl 30–59 mL/min
- No dose reduction usually needed (SmPC).
- CrCl 15–29 mL/min
- No dose reduction usually needed at CrCl ≥10 (SmPC). Watch for neurotoxicity with high intravenous doses.
- CrCl <15 mL/min (not on dialysis)
- CrCl 10–14: no change. CrCl <10: reduce the dose or extend the interval; with high-dose regimens give no more than 1 g every 8 to 12 hours (SmPC).
- Hemodialysis (intermittent)
- Dose as for CrCl <10 (high-dose regimens maximum 1 g every 8 to 12 hours). Not significantly removed by hemodialysis; no supplementary dose needed (SmPC).
- Peritoneal dialysis
- No PD-specific data; dose as for CrCl <10 (maximum 1 g every 8 to 12 hours for high-dose regimens).
- CRRT
- No data in the SmPC. Specialist input.
- Dialyzable? No: not significantly removed by hemodialysis (SmPC).
- Monitoring Liver and kidney function during prolonged courses (cholestatic jaundice, hepatitis). High anion gap metabolic acidosis with paracetamol, especially in severe kidney impairment or sepsis; check urinary 5-oxoproline if suspected. Potassium (hypokalemia at high doses). Sodium load about 51 mg per gram (SmPC 4.4).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Normal kidney function: usual age-based doses (SmPC).
- eGFR 30–59
- No pediatric-specific kidney data; adult rule (no change unless CrCl <10) is a reasonable guide.
- eGFR 15–29
- No pediatric-specific kidney data; adult rule (no change unless CrCl <10) is a reasonable guide.
- eGFR <15 (not on dialysis)
- No pediatric-specific kidney data; adult rule: reduce dose or extend interval.
- Hemodialysis (intermittent)
- No pediatric data; specialist input.
- Peritoneal dialysis
- No pediatric data; specialist input.
- CRRT
- No pediatric data; specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (May 2023). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- All ages, including newborns with caution (SmPC).
- Usual dose
- Over 10 years: adult dose. 2 to 10 years: half the adult dose. Under 2 years: one-quarter of the adult dose (SmPC).
Newborns: caution (hyperbilirubinemia, kernicterus, reduced renal excretion).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Capsule: 250 mg, 500 mg
Registered products in the Philippines
11 products registered with the Food and Drug Administration (FDA) Philippines list Flucloxacillin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products11
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CoxafenFlucloxacillin (as Sodium) | 500 mg CapsuleFoil Strip x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Aldril Pharmaceuticals, Inc.Trader: Totalcare Pharma Inc. | DR-XY32914 | Jan 31, 2027 | |
CoxafenFlucloxacillin (as Sodium) | 500 mg CapsuleFoil Strip x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Aldril Pharmaceuticals, Inc.Trader: Totalcare Pharma Inc. | DRP-15164 | Jan 31, 2027 | |
FloxacilFlucloxacillin (as Sodium) | 500 mg CapsuleBlister Pack x 10's (Box of 50's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-3964 | Jun 17, 2030 | |
FlucloxFlucloxacillin (as sodium) | 500 mg Capsule | Rx | Lloyd Laboratories, Inc. | Randril International Co., Inc. | DR-XY32639 | Nov 17, 2026Past listed date | |
FlucloxFlucloxacillin (as sodium) | 500 mg CapsuleFoil Strip x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril International Co., Inc. | DRP-15048 | Nov 17, 2026Past listed date | |
FlusaphcloxFlucloxacillin | 500 mg CapsuleAluminum Foil Strip Pack x 10's (Box of 50's and 100's) | Rx | Sapphire Lifesciences Pvt. Ltd.China | Ollen Pharma Trading, Inc. | DRP-13022 | Nov 17, 2027 | |
KhrizfloxinFlucloxacillin | 500 mg CapsuleAlu-PVDC Blister Pack x 10's (Box of 100's) FB | Rx | Sparsh Bio-Tech Pvt. Ltd.India | Khriz Pharma Trading Inc. | DR-XY49100 | May 31, 2029 | |
LucloxFlucloxacillin (as sodium) | 500 mg CapsuleStrip Foil x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-10392 | Feb 14, 2027 | |
StafloxinFlucloxacillin (as sodium) | 250 mg CapsuleFlex Foil x 10's (Box of 50's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc | DR-XY16012 | Feb 8, 2031 | |
StafloxinFlucloxacillin (as sodium) | 500 mg CapsuleFlex Foil x 10's (Box of 50's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc | DR-XY16013 | Feb 8, 2031 | |
UnbrandedFlucloxacillin (as sodium) | 500 mg CapsuleAlu/Poly foil strip x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DRP-10756 | Nov 16, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Paracetamol (acetaminophen) | Adjust or monitor | High anion gap metabolic acidosis (5-oxoproline), mainly with severe kidney impairment, sepsis or malnutrition. | Use with caution; monitor acid–base status. |
| Voriconazole | Adjust or monitor | Voriconazole levels fall markedly. | Monitor voriconazole levels; dose increase may be needed. |
| Probenecid | Minor | Slower flucloxacillin excretion. | Usually no action. |
| Bacteriostatic antibiotics | Minor | May reduce bactericidal effect. | Avoid unnecessary combination. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Nausea, diarrhea
Serious
- Cholestatic jaundice and hepatitis (may be delayed up to 2 months after stopping; most fatal cases in people over 50 or with serious underlying disease)
- Anaphylaxis
- Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis
- Interstitial nephritis
- Neutropenia, agranulocytosis
- Convulsions with high intravenous doses in kidney failure
- Clostridioides difficile colitis
- Hypokalemia; high anion gap metabolic acidosis with paracetamol
Monitoring parameters
- Liver and kidney function during prolonged courses (cholestatic jaundice, hepatitis). High anion gap metabolic acidosis with paracetamol, especially in severe kidney impairment or sepsis; check urinary 5-oxoproline if suspected. Potassium (hypokalemia at high doses). Sodium load about 51 mg per gram (SmPC 4.4). Kidney
- Liver tests in long courses and if jaundice appears; never re-challenge after flucloxacillin jaundice; kidney function in long courses
- Potassium at high doses
- Acid–base status if combined with paracetamol in at-risk patients
Pharmacokinetics
Key PK parameters
| Bioavailability | Well absorbed; absorption halved when taken with food |
|---|---|
| Half-life | 40 to 45 minutes |
| Half-life in kidney failure (ESKD) kidney | Not stated in SmPC |
| Protein binding | 90% to 95% |
| Renal excretion kidney | 20% to 50% of an oral dose in urine |
| Dialyzability kidney | No (not significantly removed by hemodialysis) |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Flucillin capsules 500 mg SmPC (PA0281/031/005) [HPRA (Ireland) product information, May 2023; no US FDA label]. https://assets.hpra.ie/products/Human/16336/Licence_PA0281-031-005_29052023122944.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Pinewood Laboratories Ltd. (2023). Flucillin (flucloxacillin) capsules 500 mg [Summary of product characteristics, licence PA0281/031/005; text revised May 2023]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/16336/Licence_PA0281-031-005_29052023122944.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .